Pharma Focus Asia
KP - Choose our fully recyclable blister films

Renibus Therapeutics Introduced First-of-its-Kind RBT-1 for Reducing Post-Operative Complications

Renibus Therapeutics has introduced first-of-its-kind RBT-1 to reduce the risk of post-operative complications in patients undergoing cardiothoracic surgery.

RBT-1, a combination of stannic protoporfin and iron sucrose, has shown promising potential in inducing various pathways related to anti-inflammation, antioxidant activity, and iron scavenging. 

The Phase 2 study of RBT-1, registered as NCT04564833, is a significant milestone in its development. This randomised, double-blind, multi-centre, placebo-controlled trial evaluated the efficacy of RBT-1 in patients undergoing elective coronary artery bypass graft (CABG) and/or cardiac valve surgery. 

The study yielded positive final results, meeting the primary biomarker endpoint as well as several key clinical outcome endpoints. These findings provide strong support for the advancement of RBT-1 into a pivotal Phase 3 study.

RBT-1 has been granted Breakthrough Therapy designation status by the U.S. Food and Drug Administration (FDA) specifically for reducing the risk of complications in patients undergoing cardiothoracic surgery. 

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Is your drug program on trackMasterControl - Manufacturing demoMasterControl - QMS demoThermo Fisher Scientific - Rapid Mycoplasma TestingThermoFisher Scientific - Save costs on your downstream process todayThermo Fisher Scientific - PeptonesMerck - Mobius® products5th Annual Pharma Manufacturing and Automation Convention 2023DUPHAT 202410TH ANNUAL GCC PHARMACY CONGRESS 202314th Annual Emirates Cardiac Society Conference 2023The International Hand & Wrist Congress 2023LabAsia 2023Pharma & Patient USA 2023Pharma Customer Engagement Europe 2023CHEMICAL INDONESIA 2024INALAB 2024